On December 12, 2024, the Stochastic Oscillator for ESLOF moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved above the 0 level on December 17, 2024. You may want to consider a long position or call options on ESLOF as a result. In of 130 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ESLOF just turned positive on December 17, 2024. Looking at past instances where ESLOF's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
ESLOF moved above its 50-day moving average on December 11, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESLOF advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESLOF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ESLOF broke above its upper Bollinger Band on December 17, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ESLOF entered a downward trend on December 13, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.152) is normal, around the industry mean (23.300). P/E Ratio (34.483) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (3.666) is also within normal values, averaging (5.667). Dividend Yield (0.018) settles around the average of (0.018) among similar stocks. P/S Ratio (3.182) is also within normal values, averaging (43.338).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESLOF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry MedicalSpecialties